PIK3CB and cholangiocarcinoma: New dual inhibitors targeted to PI3K/mTOR such as NVP-BEZ235, which exerts strong antiproliferative properties against primary cultures of intrahepatic CCA subtypes with differential drug sensitivity, have been developed [99].